1. Home
  2. EIC vs LUNG Comparison

EIC vs LUNG Comparison

Compare EIC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EIC

Eagle Point Income Company Inc.

N/A

Current Price

$9.63

Market Cap

228.8M

Sector

Finance

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.98

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EIC
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.8M
97.1M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
EIC
LUNG
Price
$9.63
$1.98
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$12.63
$5.38
AVG Volume (30 Days)
81.4K
330.8K
Earning Date
05-27-2026
04-29-2026
Dividend Yield
13.25%
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$9.08
N/A
Revenue Growth
N/A
8.01
52 Week Low
$9.17
$1.13
52 Week High
$13.55
$2.89

Technical Indicators

Market Signals
Indicator
EIC
LUNG
Relative Strength Index (RSI) 39.63 46.42
Support Level $9.33 $1.20
Resistance Level $10.14 $2.16
Average True Range (ATR) 0.11 0.13
MACD -0.03 -0.06
Stochastic Oscillator 32.08 25.12

Price Performance

Historical Comparison
EIC
LUNG

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: